AINIGMAProject reference: 627951
Funded under :
Analysing Intravital Neuronal Protein Interactions in Metabolism and Apoptosis
Total cost:EUR 161 517
EU contribution:EUR 161 517
Topic(s):FP7-PEOPLE-2013-IOF - Marie Curie Action: "International Outgoing Fellowships for Career Development"
Call for proposal:FP7-PEOPLE-2013-IOFSee other projects for this call
Funding scheme:MC-IOF - International Outgoing Fellowships (IOF)
"The high energy demand of the brain predisposes it to a variety of diseases if energy supplies are interrupted. Neurons are particularly intolerant of inadequate energy supply and die or degenerate in either an acutely or chronically disturbed metabolic environment.
Although neurodegenerative diseases are classically not considered to be caused by disturbed metabolism, bioenergetic defects are emerging as important pathophysiological mechanisms. Several glucose-metabolizing enzymes are involved in regulating cell survival or cell death in neurons and in other cell types, including the mitochondrial glucose-phosphorylating enzyme hexokinase II (HKII). A HKII-centered multiprotein complex, consisting of phosphoprotein enriched in astrocytes (PEA15) and possibly other proteins, has been demonstrated to function as a molecular switch regulating neuronal survival depending on the metabolic state. However, the molecular mechanism by which these protein:protein interactions are regulated remains elusive.
The goal of AINIGMA and of the research proposed here is to unravel the intricate connection of glucose metabolism and the regulation of cell death pathways for neuronal viability or neuronal degeneration. By combining protein interaction studies in live induced pluripotent stem (iPS) cell-derived human neurons using novel biophysical tools such as fluorescence lifetime imaging microscopy (FLIM-FRET) and high throughput live cell RNA interference (RNAi) screens, the regulation of these protein interactions will be investigated. Finally, the impact of these interactions on neuronal survival under metabolic stress as well as the metabolic consequences of these protein interactions will be investigated.
Therefore, AINIGMA will not only provide better insight into physiological and pathophysiological brain function but also form the basis for developing novel treatment approaches for acute and chronic neurodegenerative diseases."
EU contribution: EUR 161 517
Tel.: +4930 450576024
Fax: +4930 450576954